Effects of a nutrient mixture on immunohistochemical localization of cancer markers in human cervical cancer HeLa cell tumor xenografts in female nude mice

M.W. ROOMI, T. KALINOVSKY, J. CHA, N.W. ROOMI, A. NIEDZWIECKI and M. RATH

Dr Rath Research Institute, Santa Clara, CA 95050, USA

Received August 28, 2014; Accepted October 22, 2014

DOI: 10.3892/etm.2014.2127

Abstract. Although fully treatable in the early stages, once cervical cancer has metastasized, patient outcome is poor. The main objective of this study was to examine the effect of dietary supplementation with a nutrient mixture (NM) containing lysine, ascorbic acid, proline, green tea extract and other micronutrients on HeLa cell xenografts in nude female mice. Tumor growth was measured and immunohistochemical staining was evaluated for the following cancer markers: Ki67 (proliferation); matrix metalloproteinase (MMP)-2 and -9 (invasion/metastasis); vascular endothelial growth factor (VEGF) (angiogenesis); terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) and B-cell lymphoma 2 (Bcl-2) (apoptosis); cyclooxygenase 2 (COX-2) and inducible nitric oxide synthase (iNOS) (inflammation); and glutathione S-transferase π (GSTπ) (a general cancer marker). Following housing for a week, 5/6-week-old female athymic nude mice (n=12) were inoculated subcutaneously with 3x10^6 HeLa cells in 0.2 ml phosphate-buffered saline and 0.1 ml Matrigel™ and randomly divided into two groups; control group mice were fed regular mouse chow and NM group mice the regular diet supplemented with 0.5% NM (w/w). After four weeks, the mice were sacrificed and their tumors were excised and processed for histology. The NM strongly inhibited the growth of HeLa xenografts in nude mice. The mean tumor weight was reduced to 59% (P=0.001) in the mice fed the NM compared with that in the control group. In conclusion, NM supplementation strongly inhibited tumor growth and cancer markers in female nude mice injected with HeLa xenografts.

Introduction

Cervical cancer is the third most commonly diagnosed cancer and the fourth leading cause of female mortality worldwide, with >85% of the associated deaths occurring in developing countries (1). The American Cancer Society estimates ~12,360 new cases of invasive cervical cancer and ~4,020 mortalities in the United States for 2014 (2). The one-year survival rate for females with cervical cancer is 87% and the five-year survival rate is 68%. When detected early, the five-year survival rate for patients with invasive cervical cancer is 91% (3). Cervical cancer develops slowly, taking 10-15 years to develop into cancer from a pre-cancerous condition called dysplasia. Although fully treatable in the early stages, once the cancer has metastasized, patient outcome is poor.

Critical to tumor cell invasion are the processes of cell attachment, proteolytic degradation of the extracellular matrix (ECM) and migration through the disrupted matrix (4). Rath and Pauling (5) proposed that the use of nutrients, such as lysine and ascorbic acid, to target plasmin-mediated connective tissue degradation should be considered as a universal approach to control tumor growth and expansion. Binding to plasminogen active sites, lysine blocks plasminogen activation into plasmin by tissue plasminogen activator; thus, it modulates the plasmin-induced matrix metalloproteinase (MMP) activation cascade (6). We have previously developed strategies to inhibit cancer growth and its spread using complex micronutrient supplementation with select natural compounds, such as lysine, proline, ascorbic acid and green tea extract (7). This nutrient mixture (NM) demonstrated pleiotropic synergistic anticancer activity in vivo and in vitro in several cancer cell lines through the inhibition of cancer cell growth, MMP secretion, invasion, metastasis and angiogenesis (7). In previous studies we found that NM significantly inhibited the proliferation of cervical cancer HeLa cells in vitro, the secretion of MMP-2 and -9, urokinase plasminogen activator activity and Matrigel™ invasion, and enhanced tissue inhibitor of matrix metalloproteinases 2 activity (8,9). In the present study the in vivo effects of NM supplementation on...
tumor growth and cancer markers in cervical cancer HeLa cell tumor xenografts in female nude mice were investigated. The cancer cell markers studied by tumor immunohistochemistry (IHC) were as follows: Ki67 (proliferation marker); MMP-2 and -9 (metastasis markers); vascular endothelial growth factor (VEGF) (angiogenesis marker); terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) and B-cell lymphoma 2 (Bcl-2) (apoptosis markers); cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) (inflammatory markers) and glutathione S-transferase π (GSTπ) (specific cancer marker).

Materials and methods

Animals. Female athymic nude mice, approximately five weeks of age on arrival, were purchased from Simonsen Laboratories (Gilroy, CA, USA) and maintained in microisolator cages under pathogen-free conditions on a 12-h light/dark schedule for a week. All procedures were performed according to a protocol approved by an internal institutional Animal Safety Review Committee (Dr Rath Research Institute, Santa Clara, CA, USA) and followed guidelines for the humane and customary care and use of experimental animals.

Experimental design. Following housing for a week, 5/6-week-old female athymic nude mice (n=12) were inoculated subcutaneously with 3x10⁶ HeLa cells in 0.2 ml phosphate-buffered saline and 0.1 ml Matrigel (BD Biosciences, Bedford, MA, USA). Following injection, the mice were randomly divided into two groups: the control group mice were fed regular Purina mouse chow (Laboratory Rodent Diet 5001; Purina Mills, Richmond, IN, USA) and the NM mice were fed the regular diet supplemented with 0.5% NM (w/w). During the study, the mice consumed, on average, 4 g/day of their respective diets; thus, the supplemented mice received ~20 mg NM/day. After four weeks, the mice were sacrificed and their tumors were excised, weighed and processed for histology. The mean weight of the mice at the beginning and end of the study did not differ significantly between the groups.

Composition of the NM. The NM was composed of 700 mg vitamin C (as ascorbic acid and as Mg, Ca and palmitate ascorbate); 1,000 mg L-lysine; 750 mg L-proline; 500 mg L-arginine; 200 mg N-acetyl cysteine; 1,000 mg standardized green tea extract; 30 µg selenium; 2 mg copper; and 1 mg manganese. All nutrients were obtained from Vita-Tech International Inc. (Tustin, CA, USA). The certificate of analysis for the green tea extract obtained from US Pharma Lab. (North Brunswick, NJ, USA) indicated the following characteristics: Total polyphenol, 80%; catechins, 60%; epigallocatechin gallate, 35%; and caffeine 1.0%.

IHC. Tumors were placed in a formalin cassette and sent to IDEXX (Sacramento, CA, USA) and HistoTox (Boulder, CO, USA) for analyses. Formalin-fixed samples of tumors were trimmed, processed, blocked, sectioned and stained with hematoxylin and eosin, and evaluated microscopically by IDEXX Pathology. The IHC of the tumor sections conducted by HistoTox Labs assessed Ki67, MMP-2 and MMP-9, VEGF, TUNEL, Bcl-2 and iNOS.

Results

Tumor growth. The NM strongly inhibited the growth of HeLa xenografts in female nude mice. The mean tumor weight was reduced to 59% (P=0.001) in mice with NM 0.5% dietary supplementation compared with the tumor weight in the controlled-diet mice, as shown in Fig. 1.

Histology of tumors. The histology of the tumors in both groups was comparable, excepting a smaller tumor size in the
NM-treated group. A salient feature of the results was that the tumor border in the untreated groups was ill defined, whereas in the NM group the fibrous capsule was prominent (Fig. 2).

Proliferation: Ki67. The proliferation marker Ki67 showed a lower intensity and frequency of staining in the NM group compared with that in the control group. Tumors from the control group showed ≥60% of cells positive for Ki67, with the positive cells dispersed uniformly throughout the tumor amid the Ki67-negative cells (Fig. 3A and B). The NM-treated tumor sections exhibited large areas of Ki67-negative nucleated cells amid areas of positive cells (Fig. 3C and D). The Ki67-positive cells were observed to aggregate circumferentially within the tumor capsule, away from the core, in the NM-treated tumors, whereas in the untreated tumors the Ki67-positive cells were found to be distributed uniformly throughout.

Invasion/metastasis: MMP-2 and -9

MMP-2. Tumors from the control group showed intense uniform staining of MMP-2 in and around each
cell (Fig. 4A and B), while the NM-treated tumors exhibited greatly reduced central expression and secretion of MMP-2 with a ring of peripheral cells positive for MMP-2 (Fig. 4C and D).

MMP-9. The NM-treated tumors showed less MMP-9 staining than did the control-group tumors. Untreated tumors exhibited large areas of MMP-9 (Fig. 5A and B), while NM-treated tumors had large areas of cells with no MMP-9 surrounding smaller populations of cells with abundant MMP-9 (Fig. 5C and D).

Angiogenesis: VEGF. The majority of the cross-sectional areas of untreated tumors exhibited VEGF expression in a uniform distribution pattern (Fig. 6A and B). The NM-treated tumors showed markedly reduced VEGF staining, and large central areas of cells with no VEGF expression (Fig. 6C and D) were observed.

Apoptosis: TUNEL and Bcl-2

TUNEL. Abundant apoptosis occurred in both treated and untreated tumors with more apoptosis occurring in the
NM-treated group. The control group tumors showed regions of cells that were not undergoing apoptosis within larger regions of cells undergoing apoptosis for a heterogeneous pattern of normal interspersed with apoptotic cells (Fig. 7A and B). The NM-treated tumors had uniform areas of homogeneous apoptotic cells with peripheral areas of non-apoptotic cells (Fig. 7C and D). Some apoptosis was detected in the cells of the fibrous capsule of NM-treated tumors.

**Bcl-2.** High staining for Bcl-2, a pro-survival, anti-apoptotic protein, was observed in untreated tumors, whereas a reduced level of Bcl-2 was detected in the NM-treated tumors. The untreated tumors had extensive regions of Bcl-2-positive cells inside the tumors adjacent to and infiltrating regions of cells without Bcl-2 (Fig. 8A and B). The NM-treated tumors had vast regions of Bcl-2-free cells, which were clearly nucleated with considerably less Bcl-2 expression (Fig. 8C and D).

**Inflammation: COX-2 and iNOS**

**COX-2.** Tumors from the control group exhibited large dispersed regions of central COX-2 enzymes (Fig. 9A and B). The NM-treated tumors showed decreased levels of COX-2 (Fig. 9C and D).
iNOS. Tumors from the control group had extensive diffuse cytoplasmic as well as intense punctate iNOS staining within the tumor, with the majority of the tumor positive for iNOS (Fig. 10A and B). By contrast, in the NM-treated group, tumors exhibited large areas devoid of iNOS (Fig. 10C and D).

Cancer marker GSTπ. The untreated tumors had homogeneous diffuse GSTπ expression as well as intense punctate staining (Fig. 11A and B). The NM-treated tumors exhibited a similar pattern but also with regions free of GSTπ (Fig. 11C and D).

**Discussion**

In the present study, NM dietary supplementation of female nude mice challenged with HeLa xenografts resulted in a profound reduction in mean tumor weight compared with the control group. IHC staining of tumor markers confirmed this observation. The proliferation marker Ki67 was markedly reduced in the tumors from NM-supplemented mice. TUNEL staining showed abundant apoptosis in both tumor groups, with more apoptosis occurring in the NM-treated group. The control-group tumors showed regions of cells not undergoing
apoptosis within larger regions of cells undergoing apoptosis. The NM-treated tumors showed uniform areas of apoptotic cells with peripheral areas of non-apoptotic cells.

The activity of MMPs, particularly MMP-2 and-9, on the degradation of the ECM plays a critical role in the formation of tumors and metastasis, and high MMP-9 levels have been found to correlate with the aggressiveness of cancers (10). Clinical studies have noted the association of MMP expression with the progression of cervical cancers (11,12). Bonfil et al (13,14) reported that tumor necrosis was an important source of gelatinase/type IV collagenase, mainly in its 92-kDa form, and thus played a major role in tumor invasion. In the present study, tumors from the control group showed intense uniform staining of MMP-2 in and around each cell, while tumors from the NM-supplemented mice exhibited greatly reduced central MMP-2 expression surrounded by a ring of peripheral cells positive for MMP-2. In addition, tumors from NM-supplemented mice showed less MMP-9 staining than did control-group tumors. Tumors from the control group exhibited large areas of MMP-9, whereas NM-treated tumors showed large areas of cells with no MMP-9 surrounding smaller areas with abundant MMP-9. In a previous in vitro study, cervical HeLa cells showed an intense band corresponding to MMP-2 and a faint band corresponding to MMP-9, which was enhanced with phorbol 12-myristate 13-acetate treatment. The NM completely blocked MMP-9 expression at 500 µg/ml and MMP-2 expression at 1,000 µg/ml (8).

The expression of the pro-angiogenic factor VEGF, which is critical for primary tumor growth and metastasis, was also found to be significantly lower in tumors from NM-supplemented mice than that in tumors from the control group. The majority of the cross-sectional areas of the control-group tumors exhibited VEGF expression in a uniform distribution pattern. The NM-treated tumors showed markedly reduced VEGF staining with large central areas of cells having no VEGF expression. In examining specimens immunohistochemically from normal cervical epithelium, carcinoma in situ, microinvasive carcinoma and invasive cervical squamous carcinoma (SCC), Fujiwaki et al (15) reported that VEGF expression progressively increased along a continuum from normal epithelium to invasive SCC (P<0.0001). Mathur et al (16) found serum VEGF-C upregulation to be a unique marker for the early diagnosis of cervical cancer metastasis.

In addition to promoting the progression of cancer, elevated pro-inflammatory cytokine levels have been associated with a variety of pathologies, such as fatigue, depression and cachexia (17,18). In studying the inflammatory markers COX-2 and iNOS in the present study, NM supplementation of the mouse diet was found to decrease COX-2 and iNOS expression. It was found that tumors from the NM-supplemented mice exhibited reduced COX-2 staining in comparison with tumors from the control group, which exhibited large dispersed regions of central COX-2 enzymes. Furthermore, tumors from the control group had extensive diffuse cytoplasmic as well as intense punctate iNOS staining within the tumor, with the majority of the tumor positive for iNOS. By contrast, in the NM-treated group, tumors exhibited large areas devoid of iNOS. In previous studies, the NM has been shown to have an inhibitory effect on inflammatory mediators, such as COX-2, in various cancer cell lines (7,19,20).

Nuclear GSTπ is important in the diagnosis of cancer as it is expressed abundantly in tumor cells (21). This enzyme plays a role in the detoxification of both endogenous and exogenous electrophiles that can react with cellular components such as DNA. In the present study, tumors from the control group exhibited diffuse, uniform GSTπ expression, as well as intense punctate staining. Tumors from the NM-treated mice exhibited a similar pattern, but with further regions free of GSTπ.

Rath and Pauling (5) proposed that nutrients such as lysine and ascorbic acid could potentially modulate tumor growth
and expansion by acting as natural inhibitors of ECM degradation, inhibiting MMP activity and strengthening the integrity of the connective tissue surrounding cancer cells. Based on this approach, a complex of nutrients was developed to affect multiple key cancer mechanisms at once through their synergistic effects. The roles of the individual components of this mixture in relation to the critical aspects of cancer are described below. Optimal ECM structure depends upon adequate supplies of ascorbic acid, lysine and proline to maintain the synthesis and hydroxylation of collagen fibers. Furthermore, lysine contributes to the stability of the ECM as a natural inhibitor of plasmin-induced proteolysis (5,22). Manganese and copper are essential cofactors for collagen formation, and the potency of green tea extract in modulating certain processes associated with cancer progression, including cancer cell growth, metastasis and angiogenesis, is well documented (23-27). N-acetyl cysteine and selenium have been demonstrated to inhibit tumor cell MMP-9 and invasive activities, as well as the migration of endothelial cells through the ECM (28-30). Ascorbic acid demonstrates cytotoxic and antimetastatic actions on malignant cell lines (31-36) and patients with cancer have been found to have low levels of ascorbic acid (37,38). Low levels of arginine, a precursor of nitric oxide (NO), can limit the production of NO, which has been demonstrated to mainly act as an inducer of apoptosis (39).

The results presented in this study showed the potent NM-induced inhibition of tumor growth and cancer markers in female nude mice injected with HeLa xenografts, suggesting the therapeutic value of this specific nutrient complex in the treatment of cervical cancer. Supplementation with the NM has beneficial effects in modulating cancer markers of proliferation (Ki67), invasion/metastasis (MMP-2 and -9), angiogenesis (VEGF), apoptosis (TUNEL and Bcl-2) and inflammation (COX-2 and iNOS), as well as the general cancer marker GSTx. Furthermore, in contrast to the toxic side effects of current treatments, the micronutrient mixture has been shown to be a safe therapeutic agent. In a previous in vivo study addressing safety issues, we found that gavaging adult female Osteogenic Disorder Shionogi rats (weighing 250-300 g) with NM (at 30, 90 or 150 mg/day for seven days) resulted in neither adverse effects on vital organs (heart, liver and kidney) nor on the associated functional serum enzymes, indicating the safety of this mixture even at these high doses, which far exceed the normal equivalent dosage of the nutrient (40).

Acknowledgements

This study was funded by the Dr Rath Health Foundation, a non-profit organization. The authors would like to thank Professor Rajesh Agarwal, Department of Pharmaceutical Science, University of Colorado (Denver, CO, USA) for providing COX-2 IHC staining and Professor Ezio Laconi, Department of Biomedical Sciences, University of Cagliari School of Medicine (Cagliari, Italy) for the GSTx IHC staining. Special thanks to Earl Rainey for maintenance of the animal colony.

References

1. Jemal A, Bray F, Center MM, Ferley J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. American Cancer Society: Cervical cancer: What are the key statistics about cervical cancer? http://www.cancer.org/cancer/cervicalcancer/detailedguide/cervical-cancer-key-statistics. Last revised January 31, 2014; accessed June 2014.
3. Cancer.net: Cervical cancer: Statistics http://www.cancer.net/cancer-types/cervical-cancer/statistics. Last revised April 2014; accessed June 2014.
4. Fidler IJ: Molecular biology of cancer: Invasion and metastasis In: Cancer: Principles and Practice of Oncology. DeVita VT Jr, Hellman S and Rosenberg SA (eds). 5th edition. Lippincott-Raven, Philadelphia, PA, pp.135-152, 1997.
5. Rath M and Pauling L: Plasmin-induced proteolysis and the role of apoprotein(a), lysine and synthetic lysine analogs. J Orthomol Med 7: 17-23, 1992.
6. Angelescu PA, Kjoller L, Christensen L and Duffy MJ: The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72: 1-22, 1997.
7. Niedzwiecki A, Roomi MW, Kalinovsky T and Rath M: Micronutrient synergy - a new tool in effective control of metastasis and other key mechanisms of cancer. Cancer Metastasis Rev 29: 529-542, 2010.
8. Roomi MW, Kalinovsky T, Rath M and Niedzwiecki A: Modulation of VEGF expression and invasion with a novel nutrient mixture in human female cancer cell lines. Oncol Rep 28: 768-776, 2012.
9. Roomi MW, Ivanov V, Kalinovsky T, Niedzwiecki A and Rath M: Suppression of human cervical cancer cell growth by a novel nutrient mixture. Int J Gynecol Cancer 16: 1241-1247, 2006.
10. Stetler-Stevenson WG: The role of matrix metalloproteinases in tumor invasion, metastasis and angiogenesis. Surg Oncol Clin N Am 10: 383-392, 2001.
11. Asha Nair S, Karunagaran D, Nair MB and Sudhakaran PR: Changes in matrix metalloproteinases and their endogenous inhibitors during tumor progression in the uterine cervix. J Cancer Res Clin Oncol 129: 123-131, 2003.
12. Zhou CY, Yao JF and Chen XD: Expression of matrix metalloproteinase-2,9 and their inhibitor-TIMP 1,2 in human squamous cell carcinoma of uterine cervix. Ai Zheng 21: 735-739, 2002 (in Chinese).
13. Bonfils RD, Bustuoaad OD, Ruggerio RA, Meiss RP and Pasqualini CD: Cervical cancer: correlation with thymidine phosphorylase expression, endothelial growth factor expression in progression of cervical cancer In: Bladder Cancer: Etymology, Diagnosis and Treatments. Andreasen PA, Kjøller L, Christensen L and Duffy MJ: The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72: 1-22, 1997.
14. Bonfil RD, Medina PA, Gómez DE, Farias E, Lazarowski A, Lucero Gritti MF, Meiss RF and Bustuoaad OD: Expression of gelatinase/type IV collagenase in tumor necrosis correlates with cell detachment and tumor invasion. Clin Exp Metastasis 10: 211-220, 1992.
15. Fujikawa R, Hata K, Lida K, Maeda Y and Miyazaki K: Vascular endothelial growth factor expression in progression of cervical cancer: correlation with thymidine phosphorylase expression, angiogenesis, tumor cell proliferation and apoptosis. Anticancer Res 20: 1317-1322, 2000.
16. Mathur SP, Mathur RS, Gray EA, Lane D, Underwood PG, Kohler M and Creasman WT: Serum vascular endothelial growth factor C (VEGF-C) as a specific biomarker for advanced cervical cancer: Relationship to insulin-like growth factor II (IGF-II), IGF binding protein 3 (IGF-BP3) and VEGF-A [corrected], Gynecol Oncol 98: 467-483, 2005.
17. Argilés JM, Busquets S, Toledo M and López-Soriano FJ: The role of cytokines in cancer cachexia. Curr Opin Support Palliat Care 3: 263-268, 2009.
18. Deans C and Wigram SJ: Systemic inflammation, cachexia and prognosis in patients with cancer. Curr Opin Clin Nutr Metab Care 8: 265-269, 2005.
19. Roomi MW, Kalinovsky T, Roomi NW, Rath M and Niedzwiecki A: Inhibition of growth and expression of inflammation mediators in human leukemic cell line U-937 by a mixture of lysine, arginine and green tea extract. Int J Gynecol Cancer 16: 1241-1247, 2006.
20. Fidler IJ: Molecular biology of cancer: Invasion and metastasis In: Cancer: Principles and Practice of Oncology. DeVita VT Jr, Hellman S and Rosenberg SA (eds). 5th edition. Lippincott-Raven, Philadelphia, PA, pp.135-152, 1997.
21. Aliya S, Reddanna P and Thayagaraju K: Does glutathione S-transferase-Pi (GST-Pi) a marker protein for cancer? Mol Cell Biochem 253: 319-327, 2003.
22. Sun Z, Chen YH, Wang P, et al: The blockade of high-affinity insulin binding sites of plasminogen by EACA significantly inhibits prourokinase-induced plasminogen activation. Biochem Biophys Acta 1596: 182-192, 2002.
23. Valcic S, Timmermann BN, et al: Inhibitory effect of six green tea catechins and caffeine on the growth of four selected human tumor cell lines. Anticancer Drugs 7: 461-468, 1996.

24. Mukhtar H and Ahmed N: Tea polyphenols: prevention of cancer and optimizing health. Am J Clin Nutr (6 Suppl) 71: 1698S-1702S, 2000.

25. Yang GY, Liao J, Kim K, Yurtow EJ and Yang CS: Inhibition of growth and induction of apoptosis in human cancer cell lines by tea polyphenols. Carcinogenesis 19: 611-616, 1998.

26. Taniguchi S, Fujiki H, Kobayashi H, Go H, Miyado K, Sadano H and Šimikawa R: Effect of (-)-epigallocatechin gallate, the main constituent of green tea, on lung metastasis with mouse B16 melanoma cell lines. Cancer Lett 65: 51-54, 1992.

27. Hara Y (ed): Green tea: Health Benefits and Applications. Marcel Dekker Inc., New York, NY, 2001.

28. Kawakami S, Kageyama Y, Fujii Y, Kihara K and Oshima H: Inhibitory effects of N-acetyl cysteine on invasion and MMP-9 production of T24 human bladder cancer cells. Anticancer Res 21: 213-219, 2001.

29. Morini M, Cai T, Aluigi MG, et al: The role of the thiol N-acetyl cysteine in the prevention of tumor invasion and angiogenesis. Int J Biol Markers 14: 268-271, 1999.

30. Yoon SO, Kim MM and Chung AS: Inhibitory effects of selenite on invasion of HT1080 tumor cells. J Biol Chem 276: 20085-20092, 2001.

31. Cha J, Roomi MW, Ivanov V, Kalinovsky T, Niedzwiecki A and Rath M: Ascorbate supplementation inhibits growth and metastasis of B16FO melanoma and 4T1 breast cancer cells in vitamin C-deficient mice. Int J Oncol 42: 55-64, 2013.

32. Naidu KA, Karl RC and Coppola D: Antiproliferative and proapoptotic effect of ascorbyl stearate in human pancreatic cancer cells: association with decreased expression of insulin-like growth factor 1 receptor. Dig Dis Sci 48: 230-237, 2003.

33. Anthony HM and Schorah CJ: Severe hypovitaminosis C in lung-cancer patients: the utilization of vitamin C in surgical repair and lymphocyte-related host resistance. Br J Cancer 46: 354-367, 1982.

34. Maramag C, Menon M, Balaji KC, Reddy PG and Laxmanan S: Effect of vitamin C on prostate cancer cells in vitro: effect on cell number, viability and DNA synthesis. Prostate 32: 188-195, 1997.

35. Kohl WS, Lee SJ, Lee H, Park C, Park MH, Kim WS, Yoon SS, Park K, Hong SJ, Chung MH and Park CH: Differential effects and transport kinetics of ascorbate derivatives in leukemic cell lines. Anticancer Res 18: 2487-2493, 1998.

36. Chen Q, Espey MG, Krishna MC, Mitchell JB, Corpe CP, Buettner GR, Shacter E and Levine M: Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci USA 102: 13604-13609, 2005.

37. Nuñez Martin C and Ortiz de Apodaca y Ruiz A: Ascorbic acid in the plasma and blood cells of women with breast cancer. The effect of consumption of food with an elevated content of this vitamin. Nutr Hosp 10: 368-372, 1995 (In Spanish).

38. Kurbacher CM, Wagner U, Kolster B, Andreotti PE, Krebs D and Bruckner HW: Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin and paclitaxel in human breast carcinoma cells in vitro. Cancer Lett 103: 183-189, 1996.

39. Cooke JP and Dzau VJ: Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med 48: 489-509, 1997.

40. Roomi MW, Ivanov V, Netke SP, Niedzwiecki A and Rath M: Serum markers of the liver, heart, and kidney and lipid profile and histopathology in female ODS rats treated with nutrient synergy. Presented at: American College of Nutrition, Nashville, TN (abstract 86) 22: 477, 2003.